Genomed

Genomed Tangible Book Value per Share

The Tangible Book Value per Share of Genomed (GEN.WA) as of Nov 1, 2026 is 10.69 PLN. In the previous year, Tangible Book Value per Share was 8.06 PLN — a change of 32.69% (higher).

Tangible Book Value per Share

10.69PLN

YoY

32.69%

Last updated:

Tangible Book Value per Share of Genomed is 2025 10.69 PLN. Tangible Book Value per Share of Genomed was 2024 8.06 PLN. It decreases by 32.69% higher compared to the previous year.

The Genomed Tangible Book Value per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Tangible Book Value per Share
Date
Tangible Book Value per Share
Jan 1, 2018
5.68 PLN
Jan 1, 2019
5.45 PLN
Jan 1, 2020
5.71 PLN
Jan 1, 2021
6.65 PLN
Jan 1, 2022
6.92 PLN
Jan 1, 2023
7.55 PLN
Jan 1, 2024
8.06 PLN
Jan 1, 2025
10.69 PLN
The Genomed Tangible Book Value per Share history
YEARTangible Book Value per ShareYoY
10.69PLN+32.69%
8.06PLN+6.71%
7.55PLN+9.22%
6.92PLN+3.93%
6.65PLN+16.51%
5.71PLN+4.88%
5.45PLN-4.13%
5.68PLN+24.44%
4.56PLN+44.36%
3.16PLN+8.90%
2.90PLN—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genomed Stock analysis

What does Genomed do? Genomed SA generates revenue through molecular diagnostics services based on DNA sequencing, particularly Next Generation Sequencing (NGS). The company offers gene mutation analysis for over 150 congenital diseases including infertility, cancer predisposition, cystic fibrosis, Alzheimer's disease, hearing loss, coeliac disease, cardiomyopathy, and obesity. Their primary clients are healthcare providers and research institutions seeking personalized medicine solutions and genomic technology integration. Genomed SA also provides DNA sequencing, analysis, and synthesis services for the biotechnological market, targeting academic and industrial research sectors. The company's business model focuses on developing advanced diagnostic tools for medical applications, with a strong emphasis on NGS technology. Their service portfolio includes specialized genetic testing for congenital conditions and research-oriented DNA services. By concentrating on personalized medicine and gene treatment clinics, Genomed SA positions itself as a provider of specialized genomic solutions for both clinical and research markets. Genomed SA's revenue streams are derived from diagnostic testing services for congenital diseases and biotechnological DNA services. The company serves healthcare facilities requiring genetic analysis for patient care and research organizations needing genomic data for scientific advancement. Their offerings target medical professionals and biotechnology companies seeking to implement genomic technology in their operations. Genomed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genomed stock

Tangible Book Value per Share of Genomed is 10.69 PLN in 2025.

Tangible Book Value per Share of Genomed changed from 8.06 PLN to 10.69 PLN, representing a 32.69% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Tangible Book Value per Share Genomed since 2006 – with annual values, charts, and detailed analysis.

Tangible book value per share excludes intangible assets and goodwill, providing a more conservative measure of per-share net asset value.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Genomed

All Key Metrics — Genomed